Advanced RNAi architectures, modification chemistry, targeted conjugation and large-scale manufacturing from discovery through commercial supply.
Bio-Synthesis supports advanced RNAi development programs requiring more than conventional duplex siRNA synthesis. Our platform combines advanced RNAi architectures, thousands of modification combinations, stereodefined chemistry, targeted conjugation technologies and large-scale manufacturing within a single workflow.
Capabilities include Dicer-Substrate siRNA (DsiRNA), Dual-Guide Triplex siRNA, Branched Duplex siRNA, Dual-Target Branched Duplex siRNA, Divalent siRNA (di-siRNA), GalNAc-siRNA conjugates and custom RNAi formats from discovery through 1000 g+ manufacturing programs.
Build RNAi constructs beyond conventional duplex designs, including branched, multimeric, dual-guide and targeted architectures.
Control potency, stability, delivery and product quality through advanced chemistry, conjugation and analytical verification.
Scale advanced RNAi programs from feasibility studies through gram, 100 g class and 1000 g+ manufacturing supply.
RNAi is a sequence-specific gene-silencing pathway. A delivered siRNA duplex is loaded into RISC, the guide strand directs target recognition, and complementary mRNA is cleaved to reduce protein expression.
siRNA reaches the cytosol through delivery or conjugation strategy.
Guide/passenger bias controls strand selection.
The guide strand remains active in Ago2/RISC.
Complementary target mRNA is recognized.
mRNA cleavage reduces protein expression.
io-Synthesis supports advanced siRNA formats and RNAi architectures beyond standard duplex designs, including branched, linked, multimeric, targeted and dual-guide constructs.
Standard guide/passenger duplex RNAi for target knockdown, screening and lead confirmation.
Extended Dicer-substrate RNAi designs for processing, potency and strand-bias exploration.
One passenger strand supporting two active guide strands for dual-guide and multi-target RNAi programs.
A doubler-linked or branched passenger architecture designed to anneal with guide strands of the same sequence.
Two different passenger strands connected through a doubler or branching linker and annealed with two different guide strands for dual-target RNAi design.
Two siRNA duplex units connected through a linker system for multivalent RNAi, enhanced tissue distribution and long-duration silencing research.
Target-binding aptamer architecture connected to RNAi payload for cell-selective delivery research.
Liver-directed RNAi conjugates using GalNAc placement, linker geometry and duplex stabilization.
Linked or multistrand RNAi systems designed for multi-target, avidity or delivery-enabled programs.
Bio-Synthesis can support programs that go beyond duplex RNAi, including doubler-linked, branched, multiguide, multivalent, ligand-conjugated and custom annealed RNAi systems.
Bio-Synthesis supports advanced RNAi programs from early feasibility studies through commercial-scale manufacturing. The pathway is designed to maintain chemistry consistency, analytical control and supply continuity as programs advance toward larger production requirements.
Feasibility constructs, sequence panels and modification screening.
Lead selection, annealing strategy and analytical route planning.
Purified RNAi lots with expanded QC and process review.
Process refinement, documentation and release package planning.
Scale-matched purification, identity and purity confirmation.
High-volume supply planning with analytical comparability.
2′-OMe, 2′-F, 2′-MOE, LNA/BNA/cEt, XNA, base analogs and specialty sugar modifications.
PS, stereodefined Rp/Sp PS, stereopure PS, PS₂, PMO/PNA concepts and specialty backbone systems.
GalNAc, lipids, peptides, aptamers, antibodies and receptor-targeting ligands.
Doubler linkers, PEG/TEG spacers, cleavable linkers and branched linkers.
Duplex, triplex, dual-duplex and multistrand annealing support.
Novel RNAi constructs, customer-supplied designs and feasibility review.
View the complete siRNA modification, conjugation and delivery technology portfolio →
Advanced RNAi programs require more than sequence synthesis. Bio-Synthesis combines architecture design, thousands of modification combinations, stereodefined chemistry, conjugation technologies, analytical characterization and scale-up manufacturing within a single development platform.
Explore available siRNA modifications, conjugates and delivery chemistries →
Do not see your chemistry listed? Bio-Synthesis supports thousands of modification combinations, custom RNAi architectures and project-specific analytical workflows. Contact our scientific team to discuss specialized requirements.
For advanced RNAi programs, quality should not look like another set of cards. This section highlights Bio-Synthesis quality systems as a manufacturing backbone: certification, controlled workflows, analytical release and confidential project handling.
Bio-Synthesis supports advanced RNAi development with ISO quality-system positioning, documented synthesis and purification workflows, analytical verification and project-specific documentation for complex siRNA formats.
LC-MS and mass confirmation for strand identity and modifications.
HPLC/UPLC and purification strategy aligned to complexity.
Annealing confirmation for duplex, triplex and multi-strand constructs.
QC planning for doubler-linked, branched or multivalent RNAi architectures.
Support for GalNAc, lipid, peptide, aptamer and custom ligand conjugates.
CoA, project files and custom analytical packages.
Related RNAi modification, conjugation and therapeutic oligonucleotide services.
Include architecture sketch, guide/passenger sequences, modifications, branch/linker design, conjugate, scale, purification and QC.
Selected references covering RNA interference discovery, siRNA mechanism, Dicer-substrate siRNA, GalNAc-siRNA delivery, aptamer-siRNA chimeras, and clinical translation of RNAi therapeutics. These citations are provided for scientific background and technology context rather than product-performance claims.
Note: These literature references provide scientific background and technology context for RNAi mechanism, siRNA design, delivery, modification chemistry, and therapeutic translation. Selection of an RNAi architecture should be evaluated in the context of sequence design, strand bias, chemical modifications, conjugation strategy, analytical requirements, target tissue, and intended research or development workflow.
Bio-Synthesis Scientific Note: Bio-Synthesis supports custom RNAi manufacturing across duplex siRNA, Dicer-substrate siRNA, dual-guide and branched RNAi constructs, divalent siRNA, multivalent RNAi systems, ligand-conjugated RNAi technologies, GalNAc-siRNA programs and other advanced oligonucleotide architectures from discovery through large-scale manufacturing.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.